Manufacturing & Packaging

In today’s Pharma Pulse, a new national survey exposes the depth of America’s prescription access crisis, while AstraZeneca and Eli Lilly commit billions of dollars to next-generation weight-loss therapies and domestic manufacturing.

Despite steady growth since the Drug Quality and Security Act, outsourcing facilities remain constrained in scale and scope, offering targeted mitigation rather than systemic relief for persistent shortages.

The acquisition strengthens M&D’s specialty portfolio, broadens access to plasma-derived therapies, and supports phased integration focused on regulatory compliance.

In today’s Pharma Pulse, global pharmaceutical production hits a surge as manufacturers brace for US tariff shifts, while a new study reveals how smart speakers are slashing A1C levels for older adults.

The CEO of Stevanato Group discusses how tariffs, supply chain security, and long investment cycles are reshaping where and how the pharmaceutical industry manufactures.

How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.

In today’s Pharma Pulse, AbbVie joins TrumpRx, shingles vaccines reveal a longevity boost, and HER2 therapies break new ground in cancer treatment.

The company will participate in the Trump administration’s direct-to-patient drug platform, while committing $100 billion to US R&D and manufacturing.

In the final part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, explains that with plant buildouts and validation requiring three to five years, today’s reshoring momentum reflects near-term policy pressures, but global demand and overseas biosimilar growth will ultimately shape the industry’s next phase.

In today’s Pharma Pulse, Novartis expands its US radioligand footprint, and 15,000 New York City nurses go on strike.

The pharma giant will invest in a 35,000-square-foot RLT manufacturing site in Winter Park, FL as part of its $23 billion US infrastructure expansion.

In the third part of his Pharma Commerce video interview, Franco Stevanato, CEO of Stevanato Group, shares how automatic contract adjustments tied to labor, energy, and inflation—combined with the critical role of supply reliability—allow the company to pass through limited surcharges while maintaining strong client relationships.

In today’s Pharma Pulse, Amazon Pharmacy launches Novo's first oral Wegovy pill with transparent cash pricing, Johnson & Johnson triples down on North Carolina manufacturing, and new clinical data links medical debt to rising eviction risks.

In today’s Pharma Pulse, Johnson & Johnson secures a major tariff deal by joining the federal drug discount portal, while new data warns that missing early infant shots is the leading predictor of skipped MMR vaccines.

The pharma giant becomes the latest manufacturer to participate in the Trump Administration’s direct-to-patient pricing platform, aligning US drug costs with European benchmarks while reinforcing its domestic manufacturing investments.

A new Foreign Trade Zone–enabled facility in Annville strengthens the company’s temperature-controlled, compliant logistics capabilities, while accelerating customs processing and last-mile healthcare delivery.

Merck’s decision to shutter its Riverside, PA antibiotic API facility underscores how decades of cost-driven optimization have eroded domestic manufacturing of essential medicines—exposing systemic vulnerabilities in US drug supply resilience that markets alone are unlikely to fix.

The sustainable packaging company relocates its branded foam production to a more expansive Lansing site, boosting capacity, efficiency, and support for growing demand in the life science market.

The South Korea–based CDMO acquires its first US manufacturing facility in Rockville, MD, expanding its global footprint and strengthening biologics capacity.

The CDMO’s latest GMP-qualified line strengthens sterile manufacturing scalability.

The pharmaceutical giant’s new 700,000-square-foot hub aims to onshore production of key medicines and strengthen the US drug supply chain.

CoverMyMeds’ Megan Wetzel unpacks the forces behind rising specialty spend, the real impact of access barriers, and how field reimbursement teams help providers guide patients through today’s fragmented system.

AI-powered control towers and digital twins are emerging as essential tools to prevent costly supply chain failures and restore operational reliability.

The entrepreneur urges the Trump administration to eliminate costly FDA generic drug fees, part of a broader push to scale domestic production, address shortages, and challenge PBM-driven pricing models.

The agreement includes exemptions for UK-produced drugs and medical devices from Section 232 tariffs, but mandates a significant change to the UK's NICE value appraisal framework.